Ixekizumab

Ixekizumab is a prescription medication that belongs to a class of drugs called monoclonal antibodies. It is specifically designed to target and inhibit the action of a protein called interleukin-17A (IL-17A), which plays a significant role in the immune system’s response to inflammation.
Ixekizumab is primarily used for the treatment of plaque psoriasis, a chronic skin condition characterized by red, scaly patches and inflammation. By blocking IL-17A, ixekizumab helps to reduce the overactivity of the immune system, leading to a decrease in inflammation and a clearance of psoriatic lesions.
In addition to its use in psoriasis, ixekizumab has also been approved for the treatment of psoriatic arthritis, a form of arthritis that affects individuals with psoriasis. The medication helps to alleviate joint pain, swelling, and stiffness by reducing inflammation in the affected joints.
Ixekizumab is typically administered as a subcutaneous injection, with the recommended dosage being 80 mg or 160 mg every two or four weeks, depending on the patient’s response and the specific condition being treated.
Ixekizumab may cause side effects, including injection site reactions, upper respiratory infections, and headaches. Patients should consult with their healthcare provider to discuss potential risks and benefits before starting treatment with ixekizumab.